Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12029343 | 0.93 | KDM4E (0.49) | KDM4EGAAIRAK4BRAF | |
| SCHEMBL12029333 | 0.86 | ACP1 (0.40) | NPY5RGRIN1GRIN2BMAPTACP1 | |
| SCHEMBL12029338 | 0.85 | GAA (0.43) | NPY5RKDM4EGAAMAPTLMNA | |
| SCHEMBL9980916 | 0.85 | TLR7 (0.49) | NPY5RKDM4EMAPTBRAF | |
| SCHEMBL12029337 | 0.84 | RAF1 (0.48) | KDM4EGAABRAF | |
| SCHEMBL465833 | 0.84 | SCN10A (0.42) | BRAFKCNH2HRH3 | |
| SCHEMBL12029181 | 0.82 | NPY5R (0.47) | NPY5RKDM4EMAPTLMNACYP1A2 | |
| SCHEMBL12029179 | 0.81 | NPY5R (0.45) | NPY5RKDM4EGRIN1GRIN2BLMNA | |
| SCHEMBL12029180 | 0.81 | NPY5R (0.44) | NPY5RKDM4EGAAMAPTLMNA | |
| SCHEMBL12029331 | 0.81 | CNR2 (0.46) | MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2344475-B1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | NPY5R 435/4885KDM4E 1577/4885GAA 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.